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Synopsis	
	
In	this	large	cohort	retrospective	analysis	of	Group	D	retinoblastoma	cases,	conservative	
treatments	initiated	with	intravenous	chemotherapy	resulted	with	up	to	3	times	more	
number	of	examinations	under	anaesthesia	compared	to	primary	enucleation.	
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ABSTRACT		
Background	
Chemotherapy	is	increasingly	used	as	primary	treatment	for	group	D	retinoblastoma,	
whereas	primary	enucleation	is	considered	to	have	diminishing	role.	This	study	aimed	to	
compare	the	management	course,	including	number	of	examinations	under	anaesthesia	
(EUAs),	of	group	D	patients	treated	by	enucleation	versus	chemotherapy.		
Methods	
A	retrospective	analysis	of	92	group	D	patients,	of	which	40	(37	unilateral)	underwent	
primary	enucleation	and	52	(17	unilateral)	were	treated	with	intravenous	chemotherapy.	
Number	of	EUAs	was	compared	between	the	treatment	groups	in	respect	to	the	whole	
cohort,	using	univariate	and	multivariate	analysis,	and	to	unilateral	cases	only.		
Results	
Patients	were	followed-up	for	a	median	of	61	months	(mean:	66,	range:	14-156),	in	which	
time	primary	enucleated	patients	had	on	average	7	EUAs	and	chemotherapy-treated	
patients	21	EUAs	(P<0.001).	Chemotherapy,	young	age,	bilateral	disease,	multifocal	
tumours,	familial	and	germline	retinoblastoma	were	found	on	univariate	analysis	to	
correlate	with	increased	number	of	EUAs	(P≤0.019).	On	multivariate	analysis,	however,	only	
treatment	type	and	presentation	age	were	found	significant	(P≤0.001).	On	subanalysis	of	
the	unilateral	cases,	patients	undergoing	primary	enucleation	had	in	average	7	EUAs,	as	
compared	to	16	in	the	chemotherapy	group	(P<0.001).	Of	the	55	unilateral-presenting	
patients,	a	new	tumour	developed	in	the	fellow	eye	only	in	a	single	familial	case.		
Conclusion	
Group	D	patients’	families	should	be	counselled	regarding	the	significant	difference	in	
number	of	EUAs	following	primary	enucleation	versus	chemotherapy	when	deciding	on	a	
treatment	strategy.	In	this	regard,	primary	enucleation	would	be	most	beneficial	for	older	
patients	with	unilateral	disease.	
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INTRODUCTION	
Retinoblastoma	is	potentially	a	deadly	metastatic	cancer.	Early	in	the	20th	century,	when	the	
only	treatment	was	enucleation,	survival	rates	were	estimated	at	50%.	These	rates	have	
improved	considerably	since	the	middle	of	the	last	century	as	a	result	of	better	
understanding	of	the	disease,	establishment	of	specialized	centers	and	development	of	new	
management	strategies.	Currently,	survival	figures	are	estimated	at	98%	in	developed	
countries.[1]	Consequently,	while	saving	life	remains	the	primary	treatment	goal,	the	main	
challenge	now	in	battling	retinoblastoma	is	to	maximise	the	quality	of	life	for	these	patients.		
Advanced	disease	causing	irreversible	ocular	damage,	i.e.	International	Classification	of	
Retinoblastoma	(ICRB)[2]	group	E	eyes,	are	primarily	enucleated.	Many	group	D	eyes	have	
also	been	enucleated,	but	with	the	advent	of	conservative	treatments,	starting	with	plaque	
brachytherapy,[3]	external	beam	radiotherapy	(EBRT),[4]	and	chemotherapy,[5]	treatment	
paradigms	have	shifted	from	eye	removal	to	salvage.	Currently	a	large	armamentarium	is	
available	to	battle	group	D	retinoblastoma,	including	systemic	and	targeted	
chemotherapy,[6]	together	with	additional	local	modalities.	Primary	enucleation	on	the	
other	hand	has	a	diminished	role,	and	considered	by	many	to	be	moving	towards	clinical	
obsolescence.		
The	question	arises	however,	as	to	whether	primary	enucleation	for	D	eyes	has	any	
advantages	over	eye-preserving	techniques.	One	gain	relates	to	its	being	the	lowest-cost	
treatment	strategy,	compared	to	any	other	conservative	treatment.[7]	Another	possible	
advantage	would	be	that	primary	enucleation	results	in	immediate	and	total	cure	in	the	vast	
majority	of	cases,	whereas	an	eye-preserving	approach	usually	involves	numerous	
examinations	under	anaesthesia	(EUAs),	in	which	clinical	evaluation	and	medical	
interventions	are	performed.	In	this	sense,	the	number	of	EUAs	may	be	regarded	as	a	
measure	of	disease	burden,	on	patients,	as	well	as	on	their	families,	and	the	burden	
comprised	of	socioeconomic,[7,8]	mental[9]		and	possibly	physical	elements.[10]	With	
respect	to	the	latter,	it	was	suggested	that	general	anaesthesia	early	in	life	maybe	
associated	with	the	development	of	neurobehavioral	impairment.[10,11]	Although	this	
possible	association	was	not	unambiguously	proven,[12]	however	patients’	families	are	
increasingly	questioning	the	impact	that	this	may	have	on	the	child	with	the	choice	of	
conservative	treatment.		
We	have	therefore	attempted	to	quantify	the	burden	of	disease	by	the	number	of	EUAs	
received	by	patients	in	our	institution	who	had	group	D	eyes,	where	comparison	was	made	
between	those	treated	by	primary	enucleation	and	those	undergoing	attempts	at	globe	
salvage	by	chemotherapy.		The	risk	to	the	fellow	eye	and	the	age	of	the	child	at	presentation	
are	also	important	considerations	in	the	treatment	choice	of	a	group	D	eye.	Such	
information	would	be	of	great	value	when	counseling	patients’	families	regarding	possible	
treatment	strategies,	and	especially	when	considering	primary	enucleation.	
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METHODS	
This	was	a	retrospective	chart	review	of	consecutive	ICRB[2]	group	D	eyes	that	presented,	
were	treated	by	primary	enucleation	or	systemic	chemotherapy	and	monitored	at	the	
London	Retinoblastoma	Service	from	2002-2014.	The	study	was	approved	by	the	Barts	
Health	NHS	Trust	institutional	review	board	(number	6622)	in	accordance	with	the	tenets	of	
the	Declaration	of	Helsinki.	
Data	retrieved	from	medical	records	included	age	of	presentation,	gender,	family	history	of	
retinoblastoma,	presenting	signs,	clinical	data	of	first	examination,	initial	and	adjuvant	
treatments,	genetic	analysis,	number	of	EUAs,	dates	of	first	and	last	EUA,	and	follow-up	
clinical	data	until	last	examination.		
Recommendation	of	a	primary	treatment,	i.e.	enucleation	or	chemotherapy,	was	based	on	
several	factors,	including	disease	laterality,	patient’s	age	at	presentation,	family	history	of	
retinoblastoma,	clinical	findings	in	first	EUA,	in	both	eyes,	and	additional	considerations	
with	a	decision	tree	shown	in	Figure	1.		
Patients	treated	by	means	of	primary	systemic	chemotherapy	were	given	6	courses	of	
vincristine,	etoposide	and	carboplatin	(VEC),	via	a	central	line,	approximately	once	every	3	
weeks.	Adjuvant/salvage	treatments	used	as	per	clinical	scenario	included	transpupillary	
thermotherapy	(TTT),	cryotherapy,	ruthenium	plaque	radiotherapy,	intra-vitreous	
chemotherapy	(IViC,	from	2013)),	intra-ophthalmic	artery	chemotherapy	(IAC,	from	2009)	
and	EBRT.		
In	patients	who	underwent	enucleation,	after	having	their	eye	removed,	a	vicryl	mesh-
coated	hydroxyapatite	implant,	to	which	the	extraocular	muscles	were	attached,	was	
inserted,	or	an	acrylic	implant,	in	which	case	a	myoconjunctival	technique	was	used.[13]	
After	eye	removal,	tissue	was	harvested	for	RB1	mutation	analysis	and	the	eye	sent	for	
histopathologic	evaluation.		
EUAs	were	performed	for	tumour	treatment	or	screening	and	were	spaced,	tailored	per	
eye/s	status,	with	additional	considerations	that	included	patient’s	age,	family	history	of	
retinoblastoma,	presence	of	RB1	mutation,	previous	treatments	and	the	responses	to	these	
treatments.	Frequency	of	EUAs	ranged	from	once	a	week,	in	case	of	active	vitreous	seeds	
that	required	repeated	IViC,	to	once	every	6	months	in	controlled	cases.	At	the	age	of	
approximately	5	years,	after	at	least	one	year	with	no	treatments	for	active	tumours,	and	
depending	also	on	a	child’s	cooperation,	an	awake	examination	was	attempted.		
	
Statistical	Analysis	and	Definitions	
All	calculations	were	performed	using	Microsoft	Excel	2013	software	(Microsoft	
Corporation,	Redmond,	WA)	and	SPSS	software	version	17.0	(SPSS,	Inc.,	Chicago,	IL).		
Patient	characteristics	and	tumour	features	of	both	groups	were	compared	using	Chi-
squared	test.	Number	of	EUAs	consisted	of	all	occasions	in	which	a	child	was	clinically	
evaluated	or	treated	under	general	anaesthesia.	Overall	period	of	EUAs	was	defined	as	the	
time	period	in	months	from	first	(i.e.	presentation)	to	last	EUA,	and	frequency	of	EUAs	was	
calculated	as	the	number	divided	by	the	period	in	months	of	EUAs.	The	outcomes	of	the	2	
treatment	groups	were	compared	using	Fisher's	Exact	Test	and	T-Test,	for	categorical	and	
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continuous	variables,	respectively.	The	data	representing	number	of	EUAs	was	analyzed	as	
the	square	root	of	the	number	of	EUAs	in	order	to	conform	to	the	assumption	of	normally	
distributed	data.	Variables	found	significant	(P≤0.05)	on	univariate	analysis	were	further	
evaluated	using	multivariate	analysis.	
Fabian	et	al.	/	Primary	Enucleation	for	Group	D	Retinoblastoma	
	
7	
	
RESULTS	
During	the	study	period	there	were	92	group	D	retinoblastoma	patients	(104	eyes).	Of	
these,	40	(43%)	patients	(40	(38%)	eyes)	underwent	primary	enucleation	and	52	(57%)	
patients	(64	(62%)	eyes)	were	treated	by	means	of	systemic	chemotherapy	followed	by	
adjuvant/salvage	therapies.	Figure	2	shows	the	distribution	of	type	of	primary	treatment	
per	year.	Overall,	most	group	D	patients	until	2009	were	treated	by	means	of	primary	
enucleation,	whereas	from	2009	and	on,	most	were	treated	with	primary	systemic	
chemotherapy,	with	only	a	single	(4%)	primary	enucleation	performed	in	the	last	3	study	
years.		
	
Primary	enucleation	versus	primary	systemic	chemotherapy	for	group	D	eyes:	
characteristics	of	patients	and	Eyes		
The	comparison	between	the	two	primary	treatment	groups	in	terms	of	demographics,	
variables	at	presentation	and	genetic	analysis	is	shown	in	Table	1.	Overall,	in	both	treatment	
cohorts	patients	presented	across	a	relatively	wide	age	range,	with	no	significant	difference	
between	groups	(P=0.286).	There	were	no	cases	of	known	family	history	of	retinoblastoma	
in	the	enucleation	group,	compared	with	8	(15%)	in	the	chemotherapy	group	(P=0.009),	and	
positive	RB1	blood	mutation,	available	approximately	3	months	after	presentation,	was	
found	significantly	more	frequently	in	the	chemotherapy	group	(73	%	vs	20%,	P<0.001).		
	
Table	1.	Demographic,	presentation	variables	and	genetic	analysis	of	group	D	retinoblastoma	
patients:	primary	systemic	chemotherapy	versus	primary	enucleation.		
Parameter	 Primary	chemotherapy		
N=52	(%)		
Primary	enucleation		
N=40	(%)	
Significance	
Gender		
										Male		
										Female	
	
28	(54)	
24	(46)	
	
22	(55)	
18	(45)	
P=1.000	
Uni/bilateral	retinoblastoma	
										Unilateral	at	presentation		
										Bilateral	at	presentation	
																	Fellow	eye	ICRB	Group	
																														A	
																														B	
																														C	
																														D	
																														E	
	
18	(35)	
34	(65)		
		
										5	(15)	
										6	(17)	
										5	(15)	
										12	(35)	
										6	(18)	
	
37	(93)	
3	(7)	
	
										0	
										2	(67)	
										0	
										0	
										1	(33)	
P<0.001	
Age	of	diagnosis	(months)	
										Median	(mean,	range)	
	
11.0	(18.6,	0.6-144.0)	
	
24.0	(23.7,	1.0-60.0)	
P=0.286	
Presenting	signs		
										Leucocoria	
										Strabismus	
										Leucocoria	and	strabismus	
										Othera	
	
29	(56)	
13	(25)	
4	(8)	
6	(12)	
	
32	(80)	
7	(17.5)	
1	(2.5)	
0	
P=0.040	
Family	history	of	retinoblastoma	 	 	 P=0.009	
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											Negative	(sporadic)	
											Positive	(familial)	
44	(85)	
8	(15)	
40	(100)	
0	
RB1	Blood	mutation	
										Negative	
										Positive	
	
14	(27)	
38	(73)	
	
32	(80)	
8	(20)	
P<0.001	
a	Other	presenting	signs	included	periorbital	swelling	in	one	patient,	floaters	and	flashing	lights	
in	3	children	>8-year	old	and	nystagmus	in	2	patients.		
ICRB	–	International	Classification	of	Retinoblastoma.		
	
The	comparison	of	clinical	characteristics	at	presentation	between	the	primary	treatment	
groups	is	shown	in	Table	2.	In	the	primarily	enucleated	group,	significantly	more	eyes	
(P≤0.008)	presented	with	unifocal	tumours	(97.5%	and	64%	for	the	primary	enucleation	and	
systemic	chemotherapy	groups	respectively)	and	with	tumours	obscuring	the	optic	disc	
(95%	and	73%	for	the	primary	enucleation	and	systemic	chemotherapy	groups	respectively).		
With	respect	to	the	decision	tree	shown	in	Figure	1,	during	the	13-year	study	period,	97%	of	
patients	observed	the	criteria	shown	for	initial	treatment.		
	
Table	2.	First	clinical	examination	results	of	group	D	retinoblastoma	eyes:	primary	systemic	
chemotherapy	versus	primary	enucleation.		
Parameter	 Primary	chemotherapy		
N=64	(%)		
Primary	enucleation		
N=40	(%)	
Significance	
Tumour	focality		
										Unifocal	
										Multifocal	
	
41	(64)	
23	(36)	
	
39	(97.5)	
1	(2.5)	
P<0.001	
Tumour	dimensions	(mm)	
										Median	(mean,	range)	
																				Height	
																				Base	
	
	
9.7	(10.1,	4.4-19.2)	
13.0	(12.6,	7.8-19.0)	
	
	
10.4	(10.4,	6.9-13.7)	
14.2	(14.1,	9.2-17.5)	
P=1.000	
Quadrants	of	retinal	detachment		
										No	detachment	
										Local	
										1	
										2	
										3	
										4	
	
6	(9)	
12	(19)	
3	(5)	
7	(11)	
7	(11)	
29	(45)	
	
2	(5)	
6	(15)	
3	(7.5)	
3	(7.5)	
8	(20)	
18	(45)	
P=0.708	
Optic	disc	obscured		
										Not	obscured	
										Obscured	
	
17	(27)	
47	(73)	
	
2	(5)	
38	(95)	
P=0.008	
Fovea	involvement		
										Not	involved	
										Sub-foveal	fluid	
										Foveal	tumour	
	
11	(17)	
11	(17)	
42	(66)	
	
2	(5)	
6	(15)	
32	(80)	
P=0.156	
Retinoblastoma	seeds		
										No	seeds	
										Sub-retinal	
	
9	(14)	
41	(64)	
	
0	
25	(62.5)	
P=1.000	
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										Vitreous	 28	(44)	 26	(65)	
	
Of	the	primary	chemotherapy	group,	61	(95%)	eyes	received	additional	treatments.	Of	
these,	50	(78%)	had	additional	TTT	and/or	cryotherapy,	12	(19%)	underwent	plaque	
radiotherapy,	and	5	(8%)	were	treated	with	EBRT.	Of	the	latter	5	patients,	all	were	
eventually	enucleated.	Twenty	patients	(31%)	underwent	IAC	and	4	(6%)	IViC.	Twenty	four	
(46%)	patients	(24	(37.5%)	eyes)	underwent	secondary	enucleation.	Treatments	to	the	
fellow	eye	in	the	bilateral	cases	included	TTT	and/or	cryotherapy	in	33	(87%)	eyes,	plaque	
radiotherapy	in	5	(13%),	EBRT	in	6	(16%),	IAC	in	10	(26%),	IViC	in	1	(3%)	and	enucleation	
(primary	or	secondary)	in	17	(45%)	eyes.		
	
Primary	enucleation	versus	primary	systemic	chemotherapy	for	group	D	eyes:	examinations	
under	anaesthesia	
The	median	number	of	EUAs	for	the	whole	cohort	was	14	(mean:	16;	range:	2-63).	The	
median	number	of	EUAS	for	the	primary	chemotherapy	group	was	18	(mean:	21;	range:	4-
63)	and	for	the	primary	enucleation	group,	7	(mean:	7;	range:	2-14;	P<0.001;	Figure	3).		
On	univariate	analysis	(Table	3),	in	addition	to	the	primary	treatment	type,	the	following	
variables	were	found	to	associate	with	increased	number	of	EUAs:	young	age	of	
presentation,	bilateral	disease,	eyes	harboring	multifocal	tumors,	family	history	of	
retinoblastoma	and	positive	RB1	mutation	(P≤0.019).	On	multivariate	analysis,	however,	
only	age	of	presentation	(P<0.001)	and	treatment	type	(P=0.001)	were	found	to	significantly	
correlate	with	number	of	EUAs	(Figure	4	and	Table	4).	The	median	overall	period	of	EUAs	
for	the	whole	cohort	was	33	months	(mean:	35;	range:	2-106)	and	for	the	chemotherapy	
and	enucleation	groups,	40	and	27	months	(mean:	40	and	27;	range:	4-106	and	2-66)	,	
respectively	(P=0.001).	The	median	frequency	of	EUAs	for	the	whole	cohort	was	0.48	
EUAs/month	(mean:	0.52;	range:	0.13-1.43)	and	for	the	chemotherapy	and	enucleation	
groups,	0.51	and	0.31	EUAs/month	(mean:	0.58	and	0.43;	range:	0.31-1.37	and	0.13-1.43),	
respectively	(P=0.022).		
	
Table	3.	Clinical	and	treatment	parameter	correlations	with	number	of	
examinations	under	anaesthesia:	univariate	analysis.		
Parameter	 Number	of	EUAs*	
Median	(mean,	range)	
Significance	
Primary	treatment	type	
										Enucleation	
										Systemic	chemotherapy	
	
7	(7,	2-14)	
18	(21,	4-63)	
P<0.001	
Age	of	presentation	 NA**	 P=0.001	
Disease	laterality	
										Unilateral	
										Bilateral	
	
9	(10,	3-27)	
19	(22,	2-63)	
P<0.001	
Tumour	focality		
										Unifocal	
										Multifocal	
	
11	(14,	3-57)	
18	(21,	2-63)	
P=0.019	
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Germline	disease	
										Yes	
										No	
	
18	(19,	2-57)	
9	(10,	3-27)	
P<0.001	
Family	history	of	retinoblastoma	
										Yes	
										No	
	
20	(26,	17-57)	
12	(14,	2-63)	
P=0.004	
*	EUAs	–	examinations	under	anaesthesia.		
**	Non-applicable	(continuous	variable;	Figure	4).		
	
Table	4.	Clinical	and	treatment	parameter	correlations	with	number	of	examinations	under	
anaesthesia:	multivariate	analysis	(Stepwise	Linear	Regression).		
Parameter	 Unstandardized	
Coefficients	(β)	
95%	Confidence	
Interval	for	β	
Significance	
Primary	treatment	type	–	
systemic	chemotherapy	
0.98	 0.41-1.55	 P=0.001	
Age	of	presentation*	 -0.42	 (-0.06)-(-0.02)	 P<0.001	
*	Continuous	variable.		
	
Of	the	bilateral	cases,	the	fellow	eye	was	still	active	while	the	D	eye	was	already	controlled	
or	removed	in	only	7%	of	eyes.	After	excluding	these	cases	from	analysis,	in	order	to	obtain	
an	evaluation	of	EUAs	attributed	mainly	to	D	eye,	differences	between	the	2	groups	for	the		
number	of	EUAs	remained	unchanged	(mean	of	21	versus	7	EUAs	for	the	chemotherapy	and	
enucleation	groups,	respectively;	P<0.001).	On	subanalysis,	comparing	only	the	unilateral	
cases	that	underwent	primary	enucleation	(n=37)	to	those	unilateral	cases	treated	with	
primary	systemic	chemotherapy	(n=17),	again	the	latter	group	underwent	significantly	more	
EUAs	(average	of	7	and	16	EUAs	for	the	enucleation	and	chemotherapy	groups,	respectively;	
P<0.001;	Figure	5).	Further	subanalysis	on	unilateral	cases	presenting	with	unifocal	tumours,	
no	family	history	of	retinoblastoma	and	no	germline	disease,	treated	by	means	of	primary	
enucleation	(n=32)	versus	primary	intravenous	chemotherapy	(n=14),	showed	that	the	latter	
group	underwent	significantly	more	EUAs	(average	of	8	and	15	EUAs	for	the	enucleation	and	
chemotherapy	groups,	respectively;	P<0.001).	Investigating	the	treatment	course	of	both	
eyes	in	the	bilateral	cases	(excluding	D/D	cases),	in	19/23	(83%)	of	those	treated	with	
systemic	chemotherapy,	the	limiting	factor	in	terms	of	number	of	EUAs	was	the	D	eye,	
rather	than	the	fellow	eye	which	showed	tumour	control	earlier	in	the	course	of	disease.	
This	analysis	included	also	all	cases	in	which	a	D	eye	underwent	secondary	enucleation;	in	
these	cases	the	fellow	eye	was	found	stable	before	the	D	eye	was	secondarily	enucleated.	
Analyzing	the	bilateral	cases	in	which	the	D	eye	was	primarily	enucleated,	obviously,	in	the	
two	B/D	patients,	the	non-D	eye	was	the	limiting	factor.		
	
Development	of	new	tumours	in	the	fellow	eye	in	patients	presenting	as	unilateral	group	D	
The	median	age	of	presentation	of	the	unilateral-presenting	D	patients	(n=55)	was	24	
months	(mean:	26,	range:	0.6-144)	and	they	were	followed-up	for	a	median	time	of	60	
months	(mean:	61,	range:	15-125).	All	these	patients,	but	one,	remained	with	unilateral	
disease	throughout	follow-up.	This	single	patient	had	a	positive	family	history	of	
retinoblastoma	and	was	found	positive	for	RB1	gene	on	cord	blood	examination.	He	was	
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diagnosed	with	unilateral	group	D	retinoblastoma	at	the	age	of	2	weeks	and	involvement	of	
the	second	eye	at	the	age	of	8	months,	4.5	months	after	completion	of	6	VEC	cycles.	Of	
note,	of	the	unilateral	cases,	in	9	(16%),	a	blood	RB1	mutation	was	detected.		
	
Follow-up,	metastatic	spread	and	survival	
Study	patients	were	followed-up	for	a	median	time	of	61,	54	and	73	months	(mean:	66,	64	
and	69;	range:	14-156,	14-156	and	19-125)	for	the	whole	cohort,	systemic	chemotherapy	
and	enucleation	groups,	respectively	(P=0.466).	In	this	time	period,	no	cases	of	systemic	
metastatic	spread	and	no	cases	of	death	were	recorded.	
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DISCUSSION	
The	treatment	of	retinoblastoma	is	complex,	and	many	considerations	need	to	be	taken	into	
account	when	deciding	on	a	management	strategy.	A	particularly	important	time	point	is	at	
the	first	examination	when	essential	factors	are	used	to	inform	a	risk/benefit	assessment,	
and	an	optimal	treatment	plan	formulated,	where	the	alternatives	are	eye	removal	or	
preservation.	In	the	last	50	years	conservative	treatment	modalities	have	evolved	
significantly	to	become	the	mainstay	practice	for	group	D	eyes,	whereas	primary	
enucleation	nowadays	is	considered	by	many	to	be	declining.[6]	This	trend	is	reflected	in	
our	study	with	a	watershed	time	point	in	our	department	in	2009,	when	the	rate	of	group	D	
primary	enucleations	reduced	from	60%	to	19%.	This	coincided	with	the	introduction	of	IAC	
and	later	IViC	as	salvage	treatments	over	EBRT.[14]	The	improved	success	of	these	
modalities	over	EBRT	prompted	the	attempt	at	salvage	of	more	eyes	than	before.	 
The	disadvantages	of	primary	enucleation	are	obvious	and	include	total	loss	of	vision	and	
relative	disfigurement	on	the	affected	side.	The	main	advantage	however	over	eye	retention	
is	that	it	provides	immediate	cure	in	the	vast	majority	of	cases,	hence	patients	are	exposed	
to	less	medical	interventions	and	less	EUAs.	With	regard	to	the	latter,	another	advantage	of	
primary	enucleation	is	that	is	facilitates	detection	of	tumour	RB1	mutation,	or	its	ruling	out,	
hence	enabling	the	planning	of	fellow	eye	screening	with	EUAs	earlier	in	the	course	of	
disease.	In	the	present	study,	primary	enucleation	for	group	D	retinoblastoma	was	found	to	
result	in	significantly	less	consecutive	EUAs	as	compared	to	primary	chemotherapy	followed	
by	adjuvant/salvage	treatments.	This	was	true	for	the	whole	cohort,	showing	a	threefold	
difference	between	treatment	groups,	as	well	as	for	the	unilateral	cases	alone,	showing	an	
over	two-fold	difference	between	treatment	groups.	It	was	also	the	case	when	patients	with	
unilateral,	unifocal,	negative	family	history	of	retinoblastoma	and	non-germline	disease	
were	compared,	showing	a	nearly	two-fold	difference	between	treatment	groups.	Overall	
period	of	EUAs	also	differed	significantly,	with	some	chemotherapy-treated	patients	
continuing	assessments	for	up	to	10	years.	Interestingly,	the	primary	chemotherapy	group	
patients	also	underwent	EUAs	more	frequently,	as	well	as	for	longer,	further	emphasizing	
the	highly	significant	differences	in	number	of	EUAs	between	the	groups.		
Apart	from	primary	treatment	type,	young	age	of	presentation	was	found	to	independently	
correlate	with	increased	number	of	EUAs.	Repeated	EUAs	after	primary	enucleation	of	a	
unilateral	D	eye,	especially	at	young	age,	are	mainly	for	screening	purposes,	to	closely	
monitor	the	fellow	eye	in	case	new	tumours	develop,	where	genetic	testing	has	not	been	
able	to	rule	out	a	germline	mutation.	In	cases	of	unilateral	group	D	eyes	treated	by	primary	
systemic	chemotherapy,	screening	of	the	fellow	eye	is	only	a	small	part	of	the	EUA	burden,	
as	retaining	a	D	eye	is	a	difficult	process,	requiring	repeated	interventions	and	examinations	
performed	under	anaesthesia.	Further	variables	found	to	correlate	with	number	of	EUAs	
were	presence	of	multifocal	tumours	and	positive	RB1	gene,	variables	known	to	be	
linked.[15]	These	patients	are	at	increased	risk	of	developing	new	tumours	and	therefore	
regularly	undergo	more	EUAs.	Retinoblastoma	patients	with	positive	family	history	are	at	
even	greater	risk	to	developing	new	tumours,	and	are	managed	in	a	similar	manner.	
Interestingly,	these	variables	were	non-significant	on	multivariable	analysis,	further	
emphasizing	the	impact	of	age	of	presentation,	a	given	parameter,	and	more	so,	of	primary	
treatment	type,	a	selected	one.		
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Our	overall	findings	regarding	differences	in	EUAs	between	the	treatment	groups	and	
associated	predisposing	risk	factors	may	intuitively	be	predicted.	The	main	added	value	
however	of	this	report	is	that	we	have	approached	disease	burden	not	in	terms	of	clinical	
parameters	such	as	number	of	tumours	or	genetic	information	alone,	but	by	the	number	of	
EUAs.	The	approach	was	first	a	conceptual	one	-	the	focus	on	EUAs	as	a	measure	of	disease	
burden	and	secondly	to	quantify	the	number,	overall	period	and	frequency	of	EUAs.	
Amongst	the	many	clinical	parameters	that	must	be	weighed	up	by	treating	specialists,	
including	the	aim	of	retaining	the	eye	and	some	vision,	this	new	information	is	helpful	for	
families	to	decide	which	path	they	may	wish	to	follow.	The	latter	may	vary	by	geographical	
location	and	available	resources	to	the	healthcare	system	and	the	individual	families.		
The	potential	consequences	of	general	anaesthesia	in	infancy	also	need	to	be	borne	in	mind.	
Recent	paediatric	and	anaesthetic	literature	finds	this	to	be	safe	in	the	short	term.[16]	
However,	some	studies,	mainly	in	animal	models	but	also	in	humans,	have	pointed	toward	
the	possibility	of	long-term	neurological	impairment	after	anaesthesia	early	in	life.[10,17]	
Most	of	these	were	after	a	single	event	of	general	anaesthesia,	but	the	question	arises	as	to	
whether	multiple	EUAs	may	lead	to	future	neurologic	or	cognitive	impairment.	In	a	disease	
like	retinoblastoma	the	effect	of	anaesthesia	on	these	would	be	difficult	to	tease	out,	as	
there	may	be	other	important	factors	such	as	visual	loss,	disfigurement	from	surgery	as	well	
as	effects	of	chemotherapy	or	radiotherapy.	There	may	be	therefore	instances	where	
enucleation	is	desired	for	a	reduction	in	the	number	of	anaesthetics.	It	is	not	known,	
however,	whether	a	two	or	three-fold	reduction	is	of	clinical	significance.	
In	this	study	we	also	determined	the	chances	of	a	unilateral-presenting	group	D	patient	to	
develop	new	tumours	in	the	fellow	eye,	and	found	it	to	be	less	than	2%,	in	a	single	patient	
less	than	6	month	of	age	and	with	positive	family	history	of	retinoblastoma.	Our	findings	are	
in	keeping	with	those	reported	by	Abramson	et	al[18]	and	Wilson	et	al,[19]	who	found	
family	history	and	young	age	of	presentation	to	be	associated	with	increased	risk	of	
developing	new	tumours.	Interestingly,	8	(15%)	of	the	unilateral	patients	in	the	present	
study	(not	including	the	abovementioned	one)	were	found	to	be	genetic	cases,	however	
these	too	remained	unilateral	throughout	follow-up.	Based	on	the	present	findings,	the	
genetic	status	in	sporadic	cases,	which	is	usually	not	known	at	presentation,	does	not	play	a	
large	role	in	treatment-decision	making	at	the	first	EUA,	with	age	and	tumour	multifocality	
being	more	immediate	pointers	to	a	strategy.	Primary	enucleation	is	clearly	not	
recommended	in	cases	of	bilateral	disease	and	these	findings	are	reassuring	in	that	it	could	
be	offered	to	children	presenting	with	unilateral	group	D	disease	with	no	family	history.	
Being	on	the	safe	side	and	taken	together	with	the	abovementioned	findings	regarding	
EUAs,	the	best	candidates	for	primary	enucleation	would	be	older	group	D	patients	with	
unilateral	disease.		
While	disease	laterality,	age	of	presentation,	tumour	focality	and	fellow	eye	ICRB	Group	are	
crucial	factors	in	treatment	strategy	planning,	additional	factors	may	also	play	a	role.	
Unilateral	cases	in	which	the	optic	disc	was	obscured	were	significantly	more	often	treated	
by	enucleation	because	of	potential	optic	nerve	involvement	and	hence	metastasis.	
However,	optic	disc	obscuration	is	a	common	finding	in	Group	D	retinoblastoma	that	was	
found	in	82%	of	eyes	in	the	present	study;	hence	it	was	not	used	as	a	major	factor	in	the	
decision	tree.	Presence	of	RB1	mutation	is	another	important	consideration,	as	the	fellow	
eye	is	at	risk	of	tumour	formation.	However,	this	information	is	often	not	available	at	first	
EUA	in	a	sporadic	case,	when	treatment	planning	is	done.	In	a	simple	treatment	planning	
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decision	tree	there	will	be	some	features	that	cannot	be	integrated	and	indeed	new	
treatments	will	emerge	which	may	change	such	an	algorithm.	In	many	centres	IAC	is	
commonly	used	as	first	line	treatment	for	Group	D	retinoblastoma,	but	high	risk	
histopathology	features	can	occur,	in	our	series	in	13%.[20]	As	these	features	carry	a	risk	of	
metastatic	spread,	centres	such	as	ours	used	systemic	chemotherapy	as	the	main	
conservative	treatment	modality	for	Group	D	eyes	with	IAC	for	salvage.			For	the	purposes	of	
the	present	report,	this	enabled	comparison	of	outcomes	after	primary	enucleation	versus	
systemic	chemotherapy	in	a	large,	long	follow-up,	Group	D	retinoblastoma	cohort.	As	more	
safety	data	for	IAC	emerge,	our	decision	algorithm	will	also	evolve,	but	this	large	cohort	of	
systemic	chemotherapy	eyes	will	serve	as	a	benchmark	for	number	of	EUAs,	enucleation	
rate,	systemic	outcomes,	high	risk	histopathology	features	and	visual	acuity	in	salvaged	
eyes.[14,20,21]		
This	was	a	retrospective	study,	hence	its	inherent	limitations	relate	to	data	collection	and	
randomization.	Primary	chemotherapy	was	found	to	be	the	main	treatment	modality	since	
2009.	The	later	study	subjects	that	presented	in	those	years	have	been	followed-up	for	a	
shorter	time,	likely	resulting	in	underestimation	in	the	increased	EUAs	seen	in	patients	
treated	with	primary	chemotherapy.	Analysing	the	primary	enucleation	group,	two	bilateral	
cases	resulted	in	an	increased	number	of	EUAs,	because	the	fellow	non-D	eye	was	still	being	
treated	and	monitored.	Altogether,	there	were	factors	contributing	to	potential	bias	in	
calculation	of	number	of	EUAs	in	both	treatment	groups.	In	addition,	there	are	no	strict	
guidelines	as	to	how	often	EUAs	should	be	performed	or	when	to	convert	to	awake	
examinations.	Despite	these	reservations,	we	believe	that	our	findings	regarding	differences	
in	EUAs	between	the	treatment	groups	represent	the	overall	perspective	of	one	of	the	
largest	group	D	cohorts	reported	to	date	in	the	literature.		
In	summary,	in	this	cohort,	primary	enucleation	for	group	D	retinoblastoma	resulted	with	3	
times	less	EUAs,	as	compared	to	eye-preserving	chemotherapy	followed	by	additional	
treatments.	Number	of	EUAs	was	found	to	dependent	on	treatment	type	and	age	of	
presentation,	with	younger	patients	treated	with	systemic	chemotherapy	being	prone	to	
undergo	more	examinations.	In	addition,	late	involvement	of	the	fellow	non-D	eye	in	
unilateral-presenting	group	D	patients	was	found	in	this	study	to	be	a	rare	occurrence,	
noticed	only	in	a	single	6	months-old	patient	with	family	history	of	retinoblastoma.	These	
results	are	useful	additions	for	counselling	families	regarding	treatment	alternatives.	Taken	
together,	the	most	appropriate	candidates	to	benefit	from	the	advantages	related	to	
primary	enucleation	are	older	patients	with	unilateral	disease	and	no	family	history	of	
retinoblastoma.	
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FIGURE	LEGEND	
Figure	1	–Decision	tree	used	for	primary	treatment	planning	and	recommendation	to	
patients’	parents.	Additional	factors	may	play	a	role.	RB	–	retinoblastoma,	IVC	–	intravenous	
chemotherapy.		
	
Figure	2	–	Number	of	group	D	eyes	per	year	of	presentation	and	primary	treatment	
modality.		
	
Figure	3	–	Differences	in	number	of	examinations	under	anaesthesia	(EUAs)	between	the	
treatment	groups.	Analysis	of	the	whole	cohort	(N=104).	Primary	enucleation	resulted	with	
x3	less	EUAs	in	average	as	compared	to	primary	systemic	chemotherapy	(P<0.001).		
	
Figure	4	–	Relations	between	primary	treatment	type,	age	of	diagnosis	and	number	of	
examinations	under	anaesthesia	(EUAs).	Young	presentation	age	and	primary	chemotherapy	
(in	contrast	to	primary	enucleation)	were	found	on	multivariate	analysis	to	be	significant	
factors	associated	with	increased	number	of	EUAs	(P≤0.001).			
	
Figure	5	-	Differences	in	number	of	examinations	under	anaesthesia	(EUAs)	between	the	
treatment	groups.	Analysis	of	unilateral	cases	only	(N=54).	Primary	enucleation	resulted	
with	x2.3	less	EUAs	in	average	as	compared	to	primary	systemic	chemotherapy	(P<0.001).	
	
